ASCO26: Sara Tolaney, MD, MPH, ASCENT-04 - Quiz - MDSpire

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

  • July 1, 2026

Share

Original Source(s)

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

  • July 1, 2026

Related Content

Therapeutic inhibition of RAS in non-small cell lung cancer

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

  • July 1, 2026

  • 1 min
Evaluating the accuracy and communication quality of large language models in Ewing sarcoma: a comparative analysis of ChatGPT, Claude, Gemini, DeepSeek, and Grok